vs
Side-by-side financial comparison of GSI TECHNOLOGY INC (GSIT) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
GSI TECHNOLOGY INC is the larger business by last-quarter revenue ($6.1M vs $4.8M, roughly 1.3× NovaBay Pharmaceuticals, Inc.). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -49.7%, a 24.2% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs 12.2%). NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-8.2M). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs 8.6%).
Triad GSI is an American voting machine vendor based in Xenia, Ohio. Their main products are election-related computer hardware and software for counting ballots, as well as voter registration.
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
GSIT vs NBY — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $4.8M |
| Net Profit | $-3.0M | $-1.2M |
| Gross Margin | 52.7% | 65.2% |
| Operating Margin | -113.7% | -37.2% |
| Net Margin | -49.7% | -25.5% |
| Revenue YoY | 12.2% | 126.1% |
| Net Profit YoY | 25.0% | 70.5% |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.1M | — | ||
| Q3 25 | $6.4M | — | ||
| Q2 25 | $6.3M | — | ||
| Q1 25 | $5.9M | — | ||
| Q4 24 | $5.4M | $4.8M | ||
| Q3 24 | $4.5M | $0 | ||
| Q2 24 | $4.7M | $2.4M | ||
| Q1 24 | $5.2M | $2.6M |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $-3.2M | — | ||
| Q2 25 | $-2.2M | — | ||
| Q1 25 | $-2.2M | — | ||
| Q4 24 | $-4.0M | $-1.2M | ||
| Q3 24 | $-5.5M | $-1.2M | ||
| Q2 24 | $1.1M | $-1.6M | ||
| Q1 24 | $-4.3M | $-3.2M |
| Q4 25 | 52.7% | — | ||
| Q3 25 | 54.8% | — | ||
| Q2 25 | 58.1% | — | ||
| Q1 25 | 56.1% | — | ||
| Q4 24 | 54.0% | 65.2% | ||
| Q3 24 | 38.6% | — | ||
| Q2 24 | 46.3% | 66.3% | ||
| Q1 24 | 51.6% | 68.2% |
| Q4 25 | -113.7% | — | ||
| Q3 25 | -49.5% | — | ||
| Q2 25 | -34.6% | — | ||
| Q1 25 | -38.7% | — | ||
| Q4 24 | -74.9% | -37.2% | ||
| Q3 24 | -122.7% | — | ||
| Q2 24 | 23.1% | -67.4% | ||
| Q1 24 | -87.6% | -87.1% |
| Q4 25 | -49.7% | — | ||
| Q3 25 | -49.4% | — | ||
| Q2 25 | -35.3% | — | ||
| Q1 25 | -37.9% | — | ||
| Q4 24 | -74.4% | -25.5% | ||
| Q3 24 | -120.0% | — | ||
| Q2 24 | 23.1% | -66.0% | ||
| Q1 24 | -83.9% | -122.2% |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.09 | — | ||
| Q4 24 | $-0.16 | — | ||
| Q3 24 | $-0.21 | $-1.92 | ||
| Q2 24 | $0.04 | $-1.37 | ||
| Q1 24 | $-0.17 | $-29.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.7M | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $83.6M | $-129.0K |
| Total Assets | $98.5M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.7M | — | ||
| Q3 25 | $25.3M | — | ||
| Q2 25 | $22.7M | — | ||
| Q1 25 | $13.4M | — | ||
| Q4 24 | $15.1M | $430.0K | ||
| Q3 24 | $18.4M | $776.0K | ||
| Q2 24 | $21.8M | $751.0K | ||
| Q1 24 | $14.4M | $1.8M |
| Q4 25 | $83.6M | — | ||
| Q3 25 | $38.6M | — | ||
| Q2 25 | $37.4M | — | ||
| Q1 25 | $28.2M | — | ||
| Q4 24 | $29.9M | $-129.0K | ||
| Q3 24 | $33.3M | $1.1M | ||
| Q2 24 | $38.0M | $-617.0K | ||
| Q1 24 | $36.0M | $160.0K |
| Q4 25 | $98.5M | — | ||
| Q3 25 | $52.0M | — | ||
| Q2 25 | $50.5M | — | ||
| Q1 25 | $43.3M | — | ||
| Q4 24 | $44.1M | $3.4M | ||
| Q3 24 | $47.4M | $3.9M | ||
| Q2 24 | $52.3M | $3.9M | ||
| Q1 24 | $42.5M | $5.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.9M | $-1.7M |
| Free Cash FlowOCF − Capex | $-8.2M | $-1.7M |
| FCF MarginFCF / Revenue | -134.4% | -35.4% |
| Capex IntensityCapex / Revenue | 4.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.9M | — | ||
| Q3 25 | $-887.0K | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-3.6M | $-1.7M | ||
| Q3 24 | $-3.5M | $-2.4M | ||
| Q2 24 | $-4.3M | $-1.4M | ||
| Q1 24 | $-7.1M | $-2.0M |
| Q4 25 | $-8.2M | — | ||
| Q3 25 | $-906.0K | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-3.6M | $-1.7M | ||
| Q3 24 | $-3.5M | — | ||
| Q2 24 | $-4.3M | — | ||
| Q1 24 | $-7.2M | $-2.0M |
| Q4 25 | -134.4% | — | ||
| Q3 25 | -14.1% | — | ||
| Q2 25 | -27.6% | — | ||
| Q1 25 | -28.3% | — | ||
| Q4 24 | -66.1% | -35.4% | ||
| Q3 24 | -76.6% | — | ||
| Q2 24 | -92.0% | — | ||
| Q1 24 | -139.0% | -75.3% |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.7% | 0.0% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.96× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GSIT
| Distribution | $5.6M | 92% |
| Other | $459.0K | 8% |
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
